CD274 and non-small cell lung carcinoma: A post hoc analysis of the Checkmate 227 trial part 1 examined intracranial outcomes in NSCLC patients with tumor PD-L1 expression 1% or greater treated with nivolumab plus ipilimumab or chemotherapy [126].